Ras-related C3 botulinum toxin substrate 1 (Rac1) is implicated in a variety of cellular functions and is related to tumor growth and metastasis. This study aimed to explore the role of Rac1 in hypopharyngeal squamous cell carcinoma (HSCC).
Background
Hypopharyngeal squamous cell carcinoma (HSCC) is a type of aggressive head and neck squamous cell carcinoma originating from hypopharynx mucosa. Patients with HSCC are usually diagnosed at its advanced stages with poor prognosis [1, 2] . In recent years, a comprehensive treatment strategy for HSCC is combining surgery, chemotherapy, and radiotherapy [3] . Despite of the improvements in treatment strategies, patients with HSCC show high risks of local recurrence or distant metastases, with a 5-year survival rate of approximately 25-40% [4] .
Ras-related C3 botulinum toxin substrate 1 (Rac1) is one of the Rho family small GTPases. It cycles between the active form (guanosine triphosphate (GTP)-bound) and inactive form (guanosine diphosphate (GDP)-bound). Rac1 is activated by guanine nucleotide exchange factors through accelerating the exchange of GDP to GTP, and inactivated by GTPase activating proteins through promoting GTP hydrolysis. In its activated form, Rac1 interacts with its effectors to regulate multiple downstream signals [5] . Rac1 is implicated in a variety of cellular functions, such as cytoskeleton reorganization, gene transcription, cellular motility, and cell division and survival [6] [7] [8] [9] .
Elevated levels of Rac1 are found in many kinds of cancers, and Rac1 is involved in the proliferation, apoptosis, migration, invasion, and angiogenesis of cancer cells [10] [11] [12] [13] [14] . However, the role of Rac1 in HSCC remains unclear. In our present study, we explored the role of Rac1 in HSCC. The results of our study reveal that Rac1 may contribute to the growth and metastasis of HSCC.
Material and Methods

Clinical specimens
HSCC tissues and pericarcinomatous tissues were collected from 20 HSCC patients at the First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) during November 2016 to March 2017. None of these patients had previously received chemotherapy or radiotherapy. Written informed consents were signed by all patients.
Cells
FaDu cells were obtained from ZhongQiaoXinZhou Biotechnology Co., LTD (Shanghai, China). FaDu cells were grown in Minimum Essential Media (Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) and cultured in a cell incubator at 37°C with 5% CO 2 .
Transfection
Cells were seeded in a 6-well plate (3×10 5 cells/well). Twentyfour hours later, plasmids containing Rac1 shRNA or negative control (Table 1) were transfected into cells using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA). Thereafter, the cells were selected using G418 (Invitrogen). Cells stably transfected with Rac1 shRNA and negative control were marked as Rac1 shRNA and negative control, respectively. Cells without transfection were marked as parental.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Total ribonucleic acid (RNA) was extracted with a High-purity Total RNA Fast Extraction Kit (BioTeke, Beijing, China) and reversely transcribed to complementary deoxyribonucleic acid (cDNA). The messenger RNA (mRNA) level of Rac1 was detected by qRT-PCR using primers listed in Table 2 . The mRNA level in clinical specimens was calculated using 2 -DCt method and the mRNA level in cells was calculated using 2 -DDCt method.
Western blot
Proteins were extracted using radioimmunoprecipitation assay lysis buffer with 1% phenyl-methane-sulfonyl fluoride (PMSF) (Beyotime, Shanghai, China). The protein concentration was measured with a Bicinchoninic Acid Protein Assay Kit (Beyotime). Then, equal proteins from each group were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by transfer onto polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% skim milk or 1% bovine serum albumin, and then incubated with Rac1 antibody, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (1: 1000; Proteintech, Wuhan, China), Cyclin D1 antibody (1: 1000; 
Cell cycle assay
Flow cytometry was used to analyze the cell cycle with a Cell Cycle Detection Kit (Beyotime). Cells were collected, rinsed in PBS, and fixed in ice-cold 70% ethanol at 4°C for 2 h. The cells were then rinsed in phosphate-buffered saline (PBS) and resuspended in 500 μl of staining buffer. Then, 25 μl of propidium iodide and 10 μl of RNase A were added into cells and incubated for 30 min at 37°C. Cells were then analyzed with a flow cytometer (BD, Franklin Lakes, NJ, USA).
Transwell assay
To assess the migration capability, cells were made into singlecell suspensions and seeded into Transwell inserts (Corning, Tewksbury, MA, USA) in a 24-well plate (5×10 3 cells in 200 μl of serum-free cell medium). To the lower chambers, we added 800 μl of cell medium containing 30% FBS. Then, the cells were incubated in a cell incubator for 24 h, rinsed in PBS, fixed in 4% paraformaldehyde, and stained in crystal violet dye (Amresco, Solon, USA). The cells were observed and photographed with a microscope at 200× magnification. The number of migratory cells was calculated.
To assess the invasion capability, 200 μl of single-cell-suspensions (1×10 4 cells in serum-free cell medium) were added into the Transwell inserts pre-coated with Matrigel (BD), and 800 μl of cell medium containing 30% FBS was added into the lower chambers. After invasion for 24 h, the cells were stained with crystal violet dye and images were captured as described above.
Gelatin zymography
Proteins were extracted using ice-cold PBS with 1% PMSF. Following measurement of protein concentration, equal proteins from each group was injected into SDS-PAGE containing 10 mg/ml gelatin. After electrophoresis, the gel was rinsed in elution buffer and washing buffer, and then incubated in incubation buffer at 37°C for 40 h. Thereafter, the gel was kept in staining buffer for 3 h, followed by destaining buffer A for 0.5 h, destaining buffer B for 1 h, and destaining buffer C for 2 h. Images of gel were captured using a Gel Imaging System (Liuyi, Beijing, China).
Hoechst staining
Cells were seeded onto coverslips in 12 well plates (3×10 4 cells/well). After culture for 24 h, the cells were rinsed in PBS and fixed in 4% paraformaldehyde. Then, the cells were rinsed and stained in Hoechst dye (Beyotime). Images were captured with a fluorescence microscope at 400× magnification.
Animal experimental protocol
Healthy BALB/c nude mice (female, 6-weeks-old, weighing 16-18 g) were obtained from Huafukang Bioscience Co., Inc (Beijing, China). Mice were fed in a controlled environment (27±1°C, 50±10% humidity, 12 h/12 h light/dark cycles) and had free access to food and water. Mice were randomly divided into 3 groups (parental, negative control, and Rac1 shRNA) with 6 mice in each group. Rac1 shRNA cells, negative control cells, and parental cells (1×10 7 cells in 0.1 ml of serumfree medium) were injected subcutaneously into the right axilla of mice in the Rac1 shRNA group, negative control group, and parental group, respectively. Thereafter, mice and tumor bodies were observed every day. The longest diameters and
Gene name
Forward primer Reverse primer 
770
shortest diameters of tumor bodies in each group were recorded every 3 days. Thirty days later, the mice were killed and the tumor bodies were obtained. Images of mice and tumor bodies were captured and the weights of tumor bodies were recorded. This study was performed according to the Guide for Care and Use of Laboratory Animals and was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University.
Hematoxylin-eosin (HE) staining
The tumor bodies were obtained and fixed in 4% paraformaldehyde. Then, the tumor bodies were dehydrated in graded ethanol, embedded in paraffin, and cut into 5-μm sections. Thereafter, the sections were subjected to routine HE staining. Images were captured at 200× magnification.
Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay
Apoptosis in the tumor bodies were detected by TUNEL assay with an In Situ Cell Death Detection Kit (Roche, Penzberg, Germany). The tumor bodies were collected, embedded in paraffin, and cut into 5-μm sections. Then, the sections were deparaffinated in xylene, rehydrated in graded ethanol, permeabilized in 0.1% Triton X-100, and blocked with 3% H 2 O 2 . After rinsing in PBS, the sections were incubated with TUNEL reaction solution for 60 min at 37°C in the dark. The sections were rinsed in PBS and incubated with Converter-POD at 37°C for 30 min. After rinsing, the sections were developed with DAB Color-Substrate Solution (Solarbio) and counterstained with hematoxylin. The sections were observed and photographed at 400× magnification.
Statistical analysis
The results are shown as mean± standard deviation (SD). Analysis of data was performed using Student's t test or oneway analysis of variance followed by the Bonferroni multiple comparison test. P<0.05 was considered as significant.
Results
Rac1 is highly expressed in HSCC tissues
To assess the Rac1 level in HSCC, the mRNA and protein levels of Rac1 in HSCC tissues and pericarcinomatous tissues were measured. The mRNA level of Rac1 in HSCC tissues was much higher than that in pericarcinomatous tissues ( Figure 1A) . Similarly, the Rac1 protein level in HSCC tissues was higher than that in pericarcinomatous tissues ( Figure 1B ). These results reveal that Rac1 is highly expressed in HSCC.
Silencing Rac1 inhibits the growth of HSCC cells in vitro
To explore the role of Rac1 in HSCC, a Rac1-specific shRNA was used to down-regulate the Rac1 level. Prior to this study, the efficiency of Rac1 shRNA was verified. Cells transfected with Rac1 shRNA showed a lower Rac1 mRNA level and lower Rac1 protein level ( Figure 2 ) compared with the negative control group. Then, the proliferation of FaDu cells was assessed by MTT assay. Cells transfected with Rac1 shRNA showed a slower proliferation compared with the negative control group ( Figure 3A) , indicating a growth-inhibition role of Rac1 silencing in FaDu cells.
The cell cycle is one of the important events in cell growth. In our study, the effects of Rac1 silencing on the cell cycle of FaDu cells were assessed by flow cytometry. After silencing Rac1, the ratio of cells in G1 phase was increased significantly, whereas the ratios of cells in S phase and G2/M phase were decreased ( Figure 3B , Table 3 ). The protein levels of cyclins were also detected by Western blot. Cells in the Rac1 shRNA group showed lower cyclinB ( Figure 3C ), cyclinD1 ( Figure 3D ), and cyclinE ( Figure 3E ) levels. These results demonstrate that Rac1 silencing suppresses the cell cycle of FaDu cells.
Silencing Rac1 induces apoptosis in FaDu cells
The effects of Rac1 silencing on apoptosis were explored in our study. The results of apoptosis assessed by Hoechst staining showed that there were more chromatin condensations in Rac1 shRNA cells (Figure 4) . The protein levels of caspase-3, caspase-9, PARP, Bax, and Bcl-2, which have close relationships with apoptosis, were also detected in our study. After silencing Rac1, the levels of pro-caspase-3, pro-caspase-9, and PARP were decreased significantly, whereas the cleaved caspase-3, cleaved caspase-9, and cleaved PARP levels were increased ( Figure 5A-5F ). Rac1 shRNA cells also showed a higher Bax level and a lower Bcl-2 level (Figure 5G-5J) . These results show that Rac1 silencing induces apoptosis in FaDu cells.
Silencing Rac1 suppresses the migration and invasion of FaDu cells
The effects of Rac1 shRNA on migration and invasion of FaDu cells were assessed by Transwell assay. The Rac1 shRNA group showed fewer migratory cells ( Figure 6A ) and fewer invasive cells ( Figure 6B) . Moreover, the expression and activities of MMP-2 and MMP-9, which have close relationships with migration and invasion of cells, were detected. The results of Western blot showed that cells in the Rac1 shRNA group showed lower expression levels of MMP-2 and MMP-9 ( Figure 7A-7D) . The results of gelatin zymography assay also showed lower MMP-2 and MMP-9 activities in the Rac1 shRNA group (Figure 7E, 7F ). These results demonstrate that Rac1 silencing suppresses the migration and invasion of FaDu cells.
Rac1 silencing inhibits the activation of P38 MAPK signaling pathway
The activation of P38 MAPK signaling after Rac1 silencing was explored in our study. There was no significant change in the protein level of MKK3. However, the phosphorylation level of MKK3 was decreased significantly (Figure 8A, 8B) . The phosphorylation level of P38 was decreased significantly without striking changes in the protein level of P38 ( Figure 8C, 8D ). These results demonstrate that silencing Rac1 inhibits the activation of P38 MAPK signaling.
Silencing Rac1 inhibits the growth of HSCC in vivo
HSCC cells transfected with Rac1 shRNA were injected into nude mice, and then the growth of HSCC was measured. Tumor bodies in the Rac1 shRNA group showed a slower growth, with smaller tumor volumes and lower tumor weights ( Figure  9A-9C more obvious necrotic cores ( Figure 9D ) and more apoptosis ( Figure 9E ) than in the negative control group.
As P38 MAPK signaling was inhibited by Rac1 silencing in vitro, the levels of MKK3 and P38 in tumor bodies were also detected. In the Rac1 shRNA group, the level of phosphorylated MKK3 was decreased significantly, with no obvious changes in MKK3 ( Figure 10A, 10B) . The P38 level showed no significant changes, but there was a significant decrease in phosphorylation ( Figure 10C, 10D ). These results demonstrate that silencing Rac1 inhibits the P38 MAPK signal in vivo.
Discussion
Rac1 has close relationships with cancers. In our study, the role of Rac1 in HSCC was explored in vitro and in vivo. HSCC tissues showed a higher Rac1 level. Silencing Rac1 inhibited the proliferation of HSCC cells, arrested the cell cycle, and induced apoptosis. Rac1 silencing also suppressed the migration and invasion of HSCC cells. Our in vivo study showed a growth-inhibition effect of Rac1 silencing in HSCC. Moreover, in vitro and in vivo studies showed the involvement of the P38 MAPK signaling pathway in the effects of Rac1. The results of our study indicate that Rac1 has the potential to be a therapeutic target of HSCC.
Rac1 has been reported to be implicated in many diseases [15] . In the present study, HSCC tissues had high Rac1 levels, indicating that Rac1 may contribute to the pathobiology of HSCC. High Rac1 level has also been determined in many cancers, and is associated with tumor growth, metastasis, and poor prognosis [10] [11] [12] [13] [16] [17] [18] [19] .
Rac1 has close relationships with cell growth. In our study, silencing Rac1 suppressed the proliferation of HSCC cells. This indicates that Rac1 may contribute to the growth of HSCC. Rac1 downregulation was also reported to suppress the growth of osteosarcoma cells [13] and cervical cancer cells [20] . Moreover, Rac1 inhibition may enhance the sensitivity of cancer cells to radiotherapy and chemotherapy [11, 21] , which would benefit cancer therapy. Our study only showed data on Rac1 silencing. Exogenous introduction of Rac1 expression may further verify the role of Rac1 in HSCC.
Cell cycle progression is very important to cell growth. Our study showed that the cell cycle progression was arrested at G1 phase by Rac1 silencing. The report of Liu et al. also shows that the cell cycle progression of human epithelial carcinoma cells, colon cancer, and osteosarcoma is arrested at G1 phase by Rac1 inhibition, which was consistent with our study [22] .
These results indicate that Rac1 may benefit DNA synthesis and promote the cell cycle passing through the G1/S checkpoint. Moreover, Yan et al. also show that Rac1 inhibition abrogates irradiation-induced G2/M checkpoint activation, thus decreasing irradiation-induced G2/M arrest [23] , which indicates that Rac1 also regulates the G2/M checkpoint. Cyclins are important regulators of the cell cycle. with cyclin-dependent kinases in controlling the transition of cell cycle checkpoints. In our study, Rac1 silencing decreased the levels of cyclinB, cyclinD1, and cyclinE, which provides additional evidence for the effect of Rac1 on the cell cycle. These results suggest that Rac1 regulates cell cycle progression, thus contributing to the growth of HSCC.
Apoptosis is another important event affecting cell growth. In our study, Rac1 silencing increased the apoptosis of HSCC cells, which demonstrates that Rac1 may also perform an anti-apoptosis role in HSCC, thus contributing to the growth of HSCC. Analysis of recent studies shows that Rac1 plays complicated roles in cell apoptosis. In cancer cells, Rac1 is negatively correlated with cancer cell apoptosis [24, 25] . It also protects keratinocytes from UV-induced apoptosis [26] . Rac1 is also reported to be requisite for cardiomyocyte apoptosis during hyperglycemia [27] . The causes of these different roles of Rac1 in apoptosis remain unclear and need further exploration.
Rac1 silencing inhibited the proliferation, arrested the cell cycle, and induced apoptosis in HSCC cells, demonstrating a growthinhibition role of Rac1 silencing in HSSC cells. Our in vivo study also showed a growth-inhibition effect of Rac1 silencing on HSCC. Consistent with our results, Bopp et al. showed that lack of Rac1 reduces diethylnitrosamine-induced liver cancer [28] .
Compounds that inhibit Rac1 are also reported to show significant growth-inhibition effects in cancers [29, 30] . Therefore, Rac1 has the potential to be a therapeutic target for HSCC. In addition, Rac1 also affects tumor angiogenesis, which is beneficial to nutritional supplementation and cancer metastasis [14] . Moreover, inhibition of Rac1 is reported to strengthen the sensitivity of cancer cells to radiotherapy and chemotherapy [11, 23, 31, 32] . Thus, therapy targeting Rac1 may have excellent efficacy. However, as Rac1 is ubiquitously expressed throughout the body, targeted delivery systems need further development to avoid adverse effects.
Metastasis is a main cause of mortality in cancer patients. An estimated 90% of cancer-associated deaths are caused by metastasis [33] . Rac1 can regulate cytoskeleton reorganization, promote the formation of lamellipodia, and is associated with the metastasis of many cancers [5, 14, [34] [35] [36] [37] . In our study, silencing Rac1 inhibited the migration and invasion of HSCC cells, indicating that Rac1 may also contribute to HSCC metastasis. MMPs play important roles in extracellular matrix degradation, which contributes to the metastasis of cancer cells [38, 39] . In our study, the expression and activities of MMP-2 and MMP-9 were all decreased by Rac1 silencing. These results provide additional evidence for the metastasis-inhibition effect of Rac1 silencing in HSCC cells. Rac1 is also reported to be involved in the epithelial-mesenchymal transition, which is one of the important events in cancer cell metastasis [40] . As a limitation of our study, we lacked experiments regarding tumor metastasis in vivo. Although Lee et al. showed that inhibition of Rac1 can decrease tumor metastasis in vivo [41] , the effect of Rac1 silencing on the in vivo metastasis of HSCC needs further exploration.
Rac1 interacts directly with several signals to regulate cell growth, inflammatory responses, and cell-cell contacts [14] . MAPK family members can be activated by Rac1. P38 MAPK signalling is implicated in diverse cellular events through its extensive downstream molecules [42] . In our study, the activation of P38 MAPK signalling was inhibited by Rac1 silencing, both in vivo and in vitro. These results suggest that Rac1 affects the A B growth and metastasis of HSCC through P38 MAPK signalling.
Other signals, such as Wnt [43] , are also downstream of Rac1, and they may also be involved in the role of Rac1 in HSCC, but further explorations are needed to assess this.
Conclusions
In our study, Rac1 showed a high level in HSCC tissues. Silencing Rac1 inhibited the growth of HSCC in vitro and in vivo. Rac1 silencing was also found to suppress the metastasis of HSCC cells. This indicates that Rac1 may act as an oncogene in HSCC and has the potential to become a promising therapeutic target for HSCC.
